Diarrhea News and Research

Latest Diarrhea News and Research

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg.

4 May 2013

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from AUGMENT/COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) for the treatment of Chronic Obstructive Pulmonary Disease (COPD), delivered in the Pressair™ inhaler (Genuair® outside the USA).

2 May 2013

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair (Genuair outside the USA) inhaler.

2 May 2013

PET/CT may enhance detection of inflammatory bowel diseases in the future

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, may be detected and monitored more effectively in the future with positron emission tomography/computed tomography, according to research published in the May issue of The Journal of Nuclear Medicine.

2 May 2013

Researchers say tiny thymus teaches immune system to ignore foreign bacteria in gut

The tiny thymus teaches the immune system to ignore the teeming, foreign bacteria in the gut that helps you digest and absorb food, researchers say.

30 Apr 2013

Opinion pieces address World Malaria Day

On Thursday, the international community recognized World Malaria Day, observed annually on April 25. This year's theme was "Invest in the future. Defeat malaria."

29 Apr 2013

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.

29 Apr 2013

Globalpost examines implications of U.S. budget negotiations on global health spending

In the first article in a special report titled "The Seven Million," which looks at "the many challenges faced worldwide in an effort to reduce child mortality" and is "supported through a partnership with the Kaiser Family Foundation," GlobalPost examines the implications of U.S. budget negotiations on global health spending.

26 Apr 2013

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

Vertex Pharmaceuticals Incorporated today announced new data from an interim analysis of the exploratory global Phase 3b CONCISE study evaluating the potential to shorten total treatment with telaprevir combination therapy to 12 weeks in certain people with genotype 1 chronic hepatitis C virus infection who have the IL28B CC genotype.

25 Apr 2013

University of Guelph researchers develop carbohydrate-based vaccine against gut bug

A first-ever vaccine created by University of Guelph researchers for gut bacteria common in autistic children may also help control some autism symptoms.

25 Apr 2013

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals for the treatment of hepatitis C virus infection, continue to demonstrate high sustained viral response rates against genotype 1 HCV, across patient types.

24 Apr 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections.

23 Apr 2013

Unnecessary use of antibiotics in elderly women in EDs increases risk of unintended consequences

Older adults represent an important and growing demographic in emergency departments across the country, with urinary tract infections being one of the leading causes for ED visits.

23 Apr 2013

GAPPD presents opportunity to meld global, local agendas

"Beyond integration across the two diseases, the [Global Action Plan for the Prevention and Control of Pneumonia and Diarrhea (GAPPD) released by the WHO and UNICEF last week] is an opportunity to meld global and local agendas, giving national governments a comprehensive tool to determine the specific plans, investments, and partners needed to address the unique needs of their countries and achieve the greatest health impact for their citizens," PATH CEO Steve Davis writes in the Huffington Post's "Global Motherhood" blog.

18 Apr 2013

Study suggests strain with Haiti cholera mutations may increase severity of disease

The cholera strain that transferred to Haiti in 2010 has multiple toxin gene mutations that may account for the severity of disease and is evolving to be more like an 1800s version of cholera, reports a new Northwestern Medicine study.

17 Apr 2013

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.

17 Apr 2013

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Acorda Therapeutics, Inc. today announced that a proof-of-concept trial found dalfampridine extended release tablets, marketed as AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, improved walking in people with post-stroke deficits.

16 Apr 2013

Luminex's MAGPIX instrument gets FDA approval

Luminex Corporation today announced it has received U.S. FDA clearance of its MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel.

From Luminex 16 Apr 2013

Diarrhea News and Research

Latest Diarrhea News and Research

FDA approves sNDA for SUSTIVA for treatment of HIV-1 infected pediatric patients

Aclidinium and formoterol combination demonstrates significant lung function improvement in the second pivotal efficacy trial

Forest Laboratories, Almirall report positive topline results from AUGMENT COPD

PET/CT may enhance detection of inflammatory bowel diseases in the future

Researchers say tiny thymus teaches immune system to ignore foreign bacteria in gut

Opinion pieces address World Malaria Day

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Globalpost examines implications of U.S. budget negotiations on global health spending

Vertex presents data of telaprevir Phase 3b CONCISE study in people with genotype 1 chronic HCV

University of Guelph researchers develop carbohydrate-based vaccine against gut bug

Phase IIb Aviator study demonstrates high SVR rates against genotype 1 HCV

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

Unnecessary use of antibiotics in elderly women in EDs increases risk of unintended consequences

GAPPD presents opportunity to meld global, local agendas

Study suggests strain with Haiti cholera mutations may increase severity of disease

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Acorda Therapeutics reports positive data from dalfampridine-ER post-stroke deficits trial

Luminex's MAGPIX instrument gets FDA approval

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Diarrhea News and Research

Latest Diarrhea News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in